Comparison 1. Certolizumab pegol versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical remission at week 8	4	1485	Risk Ratio (M‐H, Random, 95% CI)	1.36 [1.11, 1.66]
2 Clinical response at week 8	4	1485	Risk Ratio (M‐H, Random, 95% CI)	1.29 [1.09, 1.53]
3 CRP at week 8 (log‐scales of geometric mean CRP ratio between baseline and week 8)	4	1271	Mean Difference (IV, Random, 95% CI)	‐0.37 [‐0.49, ‐0.24]
4 IBDQ total score at week 8 (mean change from baseline)	4	1315	Mean Difference (IV, Random, 95% CI)	2.12 [‐1.27, 5.50]
5 Adverse events	4	1485	Risk Ratio (M‐H, Random, 95% CI)	1.03 [0.97, 1.10]
6 Serious adverse events	4	1485	Risk Ratio (M‐H, Random, 95% CI)	1.35 [0.93, 1.97]
7 Withdrawals due to adverse events	4	1485	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.57, 1.78]
8 Clinical remission at week 8 (Subgroup analysis based on CZP doses)	4		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
8.1 Certolizumab pegol 100mg	1	99	Risk Ratio (M‐H, Random, 95% CI)	2.48 [0.81, 7.58]
8.2 Certolizumab pegol 200mg	2	142	Risk Ratio (M‐H, Random, 95% CI)	1.84 [0.75, 4.50]
8.3 Certolizumab pegol 400mg	4	1244	Risk Ratio (M‐H, Random, 95% CI)	1.30 [1.06, 1.60]
9 Clinical remission at week 8 (Subgroup analysis of no previous treatment with TNF‐α inhibitors)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
10 Clinical remission at week 8 (Subgroup analysis of CRP levels at baseline)	4		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
10.1 CRP ≥ 10 mg/L	4	702	Risk Ratio (M‐H, Random, 95% CI)	1.59 [1.17, 2.16]
10.2 CRP < 10 mg/L	3	762	Risk Ratio (M‐H, Random, 95% CI)	1.15 [0.88, 1.50]
11 Clinical remission at week 8 (Sensitivity analysis of excluding studies with high risk of bias)	3	1193	Risk Ratio (M‐H, Random, 95% CI)	1.29 [1.05, 1.59]
12 Clinical remission at week 8 (sensitivity analysis of using available case data)	4	1463	Risk Ratio (M‐H, Random, 95% CI)	1.36 [1.11, 1.67]
13 Clinical remission at week 8 (Sensitivity analysis of studies with the approval dosing regimen)	3	1147	Risk Ratio (M‐H, Random, 95% CI)	1.28 [1.03, 1.57]